Total VTE · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether low molecular weight heparin and idraparinux changes recurrent venous thromboembolism compared with standard therapy (very low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heparin‐induced thrombocytopenia ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: pain on injection (solution deposition), Heft-Parker VAS 0-170 mm · patients treated with subcutaneous heparin injections
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients treated with subcutaneous heparin injections
1 finding from 1 review
Bruise size 48 hours after injection (mm/mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
Bruise size ‐ 60 hours after injection (mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
Bruise size ‐ 72 hours after injection (mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
Bruise incidence ‐ 48 hours after injection · patients treated with subcutaneous heparin injections
Slow may leads to lower bruise incidence ‐ 48 hours after injection compared with fast subcutaneous heparin injection (low certainty).
2 findings from 1 review
CVC occlusion rate per 1000 catheter days Ability to infuse solution through CVC · infants and children with a long‐term CVC
It is very uncertain whether does normal saline flushing in long‐term central venous catheters… changes CVC occlusion rate per 1000 catheter days: ability to infuse… compared with heparin flushing (very low certainty).
1 finding from 1 review
CVC‐associated blood stream infection rate per 1000 catheter days Incidence of positive blood culture · infants and children with a long‐term CVC
Does normal saline flushing in long‐term central venous catheters… showed no clear difference in CVC‐associated blood stream infection rate per 1000 catheter days:… compared with heparin flushing (low certainty).
1 finding from 1 review
Duration of CVC placement (days) · infants and children with a long‐term CVC
1 finding from 1 review
Major VTE events bilateral ascending venography1 · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in major VTE events bilateral ascending venography1 compared with low molecular weight heparins (low certainty).
1 finding from 1 review
All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).
1 finding from 1 review